Xin Lang Cai Jing·2025-12-25 02:25Core Viewpoint - Nocera Biopharma's stock has experienced a decline recently, despite a significant year-to-date increase, indicating potential volatility in the market [1][2]. Group 1: Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals [2]. - The company specializes in areas with unmet clinical needs, particularly in oncology and autoimmune diseases, with a product pipeline that includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723 [2]. - Revenue composition as of the latest report shows that 87.67% comes from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [2]. Group 2: Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85% [2]. - The company recorded a net profit attributable to shareholders of -64.41 million yuan, which is a 76.61% increase compared to the previous period [2]. Group 3: Stock Performance and Market Activity - As of December 25, Nocera Biopharma's stock price was 21.41 yuan per share, with a market capitalization of 37.781 billion yuan [1]. - The stock has increased by 74.35% year-to-date but has seen a decline of 2.68% over the last five trading days, 17.30% over the last 20 days, and 23.75% over the last 60 days [1]. - Recent trading activity indicates a net outflow of 13.5825 million yuan from major funds, with significant selling pressure observed [1]. Group 4: Shareholder Composition - As of September 30, 2025, the number of shareholders increased to 16,500, up by 8.66% from the previous period [2]. - Notable changes in the top ten shareholders include a decrease in holdings by some funds and the entry of new shareholders, indicating shifts in institutional interest [3].